Weight loss varies significantly across individuals
GLP-1 is similar to but unlike GIP, actions of GLP-1 are better preserved in type 2 diabetes mellitus (T2DM) patients, which makes it a highly desirable target for drug discovery for T2DM (Sharma and Bhatia, 2020)
Xiong Y, Zhou F, Liu Y, Yi Z, Wang X, Wu Y, et al
Qualifying conditions include type 2 diabetes, prediabetes, high blood pressure, high cholesterol, sleep apnea, PCOS, fatty liver disease, cardiovascular disease, insulin resistance, metabolic syndrome, and weight-related joint pain
Prescriptions are written by licensed providers through Arora Health, an independent 50-state medical service organization
(3) In late 1999, a clinical trial was carried out on eight test subjects where Ipamorelin was presented every 15 minutes for a set period